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ence of HBsAg (overt infection), occult HBV infection (OBI, deﬁned
as presence of HBV DNA in the absence of HBsAg), might be also
accounted in some non-or hypo-response cases.
Methods & Materials: : Sera from 120 HBsAg negative HCWs
with low and moderate levels of anti-HBs, <10 IU/mL (group 1)
and <100 IU/mL (group 2) respectively, were selected and were
examined for OBI by sensitive real time PCR regardless of HBV sero-
logical proﬁles. Direct sequencing on surface genes was carried out
in OBI-positive cases.
Results: Four (3.3%) were positive for OBI. All were negative for
anti-HBc. Two of the positive cases hadmoderate levels of anti-HBs
(10-100 IU/mL) fromgroup2.No signiﬁcant differenceswere found
between the two groups in terms of risk factors or serological data.
No mutations were found in surface proteins of OBI cases.
Conclusion: OBI in these subjects might be due to other fac-
tors rather than presence of “a” determinant mutations. Health
careworkers with inadequate tomoderate levels of anti-HBs (<100
IU/mL) following vaccination, regardless of their serological proﬁle
for HBV, should be tested for the presence of HBV DNA by sensitive
molecular tests. Anti-HBc is not a reliable marker for suspicion of
OBI, especially in high-risk group individuals.
http://dx.doi.org/10.1016/j.ijid.2016.02.919
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Background: Hand, foot and mouth disease (HFMD) mainly
caused by enterovirus 71 (EV71) infection has become one of the
major public health issues in China. Understanding of population’s
immunity against EV71 and the epidemic changes of enterovirus
are beneﬁt to the future therapeutic and prophylactic intervention
of HFMD.
Methods & Materials: Multistage stratiﬁed cluster sampling
method was used for the sampling. A total of 623 patients infected
with EV-71 during Jan and Dec, 2014 are selected from 3 represen-
tative city circles in Chengdu. The EV71-IgG levels of all the samples
were detected by enzyme-linked immunosorbent assay. Statistical
data comparisons between various factorswere analyzed bymeans
of Pearson 2, unpaired T-test, or Fisher’s exact test. Correlation
analysis is used to test the signiﬁcance of the relationship between
the positive rates and ages.
Results: It is of no statistical signiﬁcance (P >0.05) when it
comes to the differences of the antibody positive rates of EV71-
IgG between male and female, circles and circles as well as urban
and rural areas. The positive rates of the groups with the age
ranging 0∼1 (61.37%) and 1∼2 (52.33%) are much higher than
that of 3∼4, 5∼6, 7∼9, 10∼14, ≥15 groups, with the rates 29.89%,
22.52%, 14.54%, 11.26%, 7.33%, respectively (all P <0. 05). The pos-
itive rate remained relatively high in preschool children aged<2
years and thereafter decreased sharply to more than 50% in indi-
viduals aged>5 years. In terms of the correlation of positive rate
of EV71 of the monitoring data and age of patients, it is negatively
correlated when subjects are under the age of 5 while it turns to be
positive when subjects are over the age of 5.
Conclusion: It is clearly identiﬁed that the population with the
age under 5, especially the infants aged 2 years or younger, are
the focus of the prevention and control of HFMD. Our study could
play an important role in the protection of susceptible population
and the evaluation of the immune effect of the upcoming vaccine
application.
http://dx.doi.org/10.1016/j.ijid.2016.02.920
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Background: Dengue is the most rapidly spreading arboviral
disease in the world. Strain variations within the four dengue
serotypes classify the virus into genetically distinct groups within
serotypes called genotypes. Several studies have shown that dis-
ease outcome is associated with the genotype involved. Northeast
Region of India comprises of 8 states and has witnessed several
Dengue outbreaks in recent years. During 2015, a massive Dengue
outbreak occurred in Pasighat, Arunachal Pradesh, India reporting
around 2000 cases. All four serotypes have been reported from this
region but studies on the genotype of the virus is lacking. This study
was undertaken with an objective to elucidate the genotype of
Dengue virus circulating in Arunachal Pradesh during the outbreak.
Methods&Materials: A total of 115 Dengue suspected samples
were collected from Pasighat General Hospital, Arunachal Pradesh.
ScreeningofDengueNS1antigenorAnti-Dengue IgMantibodywas
donedependingupon thedurationof samplecollectionandonsetof
symptom. IgG ELISA was done to determine whether the infection
was primary or secondary. RT-PCR was performed using speciﬁc
primers to amplify C-prM gene region. The obtained sequences
were analyzed using BioEdit software and a phylogenetic tree was
constructed in MEGA 6 software.
Results: Total 50 sampleswereDenguepositive by eitherNS1or
IgM ELISA of which eight (16%) cases were due to secondary infec-
tion. Dengue virus RNA was detected in 28 samples. Serotype 1
was found to be predominant during the outbreak. Phylogenetic
analysis of the obtained sequences using Maximum Likelihood
method and Kimura-2 parameter model revealed that the circu-
lating Dengue virus-1 during the outbreak belonged to Genotype
III.
Conclusion: This is the maiden report on genotyping of Dengue
virus 1 from this region of India. Studies have shown that the emer-
gence of newer dengue serotype/ genotype after a gap have always
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been associated with massive outbreaks; therefore it is necessary
to carry out active surveillance to monitor Dengue virus epidemi-
ology. Further study on pathogenecity of Dengue virus 1 as well as
other serotypes circulating in this region is in scope of this study.
http://dx.doi.org/10.1016/j.ijid.2016.02.921
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Background: Co-circulationof Japanese encephalitis Virus (JEV)
and West Nile Virus (WNV) has been accounted in India. Both
viruses are antigenically related and belong to the Japanese
encephalitis (JE) serocomplex. Recently, the Government of India
introduced the live attenuated JE vaccine SA 14-14-2 in routine
immunization program for children and mass vaccination cam-
paign among adults in highly JE endemic areas of Assam, Northeast
India. However, the protection elicited by the JE vaccine against
the circulating JEV and WNV in this region have not been stud-
ied. Thus, we investigated whether a single dose of this vaccine
provided protection against local JEV and WNV isolates in animal
model.
Methods & Materials: Eight groups (n=6) of four-six week old
Swiss albino mice were inoculated sub-cutaneously with the JE
vaccine. Four weeks post immunization, three mice groups were
challenged intra-peritoneally with three JEV and four WNV each
comprising of both archival and circulating strains. Onemice group
served as a control with no virus challenge. Micewere observed for
21 days.
Results: Theprotection rates against three JEV strains (genotype
III) were 100%. However, we noticed limited protection against the
fourWNV stains (Lineage V). But, interestingly, the protection rates
against archival WNV strains 804994 and circulating WNIRGC07
were 50% and 33.33% respectively. Whereas, no protection was
conferred by the vaccine to WNV archival G22886 and circulating
WNIRTC08 strains.
Conclusion: The study showed total protection against JEV
strains which may be due to the same genotype of the vaccine
(Genotype III) as that of the local JEV strains. However, JEV vaccine
was found to elicit partial cross protection to a circulating WNV
strain which was reported to be a variant. It is noteworthy that no
protection was observed against the other circulating WNV strain.
Thus for immunization strategies, limited cross protection against
heterologous viruses of the JE serocomplex must be considered.
http://dx.doi.org/10.1016/j.ijid.2016.02.922
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Background: WHO has identiﬁed Dengue as the fastest spread-
ingmosquito-borne disease in theworld. Approximately 96million
people develop clinical Dengue annually, of which 1 in every 200
proceeds to develop potentially fatal Dengue haemorrhagic fever
and/or shock syndrome (DHF/DSS). Depending on the availability
of appropriate supportive treatment, the case-fatality rate varies
from 3.5% to 50%. The debilitating and painful nature of the disease,
together with the lack of an accurate method to predict DHF/DSS,
resulted in unnecessary over-hospitalisation. The situation iswors-
ened during epidemic years, in both developed (e.g. Singapore in
2004/2005) anddevelopingcountries (e.g. India in2015) alike. Elec-
tive surgeries and non-emergency admissions had to be cancelled
to release health resources for Dengue inpatients. Our laboratory
previously discovered a panel of novel serum biomarkers that
can predict DHF/DSS with a sensitivity and speciﬁcity of 90% and
91%, respectively. As majority of Dengue-endemic countries are
developing countries, we sought to evaluate how test performance
wouldbe affectedbyusing only onebiomarker (BM1), so as tomake
the test more affordable.
Methods & Materials: 109 Dengue patients were enrolled from
the Colombo South Teaching Hospital and National Hospital of Sri
Lanka. The study was approved by the Ethics Review Committee
of the University of Sri Jayawardanapura, and all patients provided
informedconsent. Bloodsampleswerecollectedwhensubjectsﬁrst
presented themselves at the hospitals. Serum BM1 concentration
was measured using a quantitative ELISA developed in-house. All
statistical analyses were performed using R version 3.1.2.
Results: 60 subjects were diagnosed with DHF while 49 had
classical Dengue fever. Based on only serum BM1 concentration,
the performance of the test to predict DHF/DSSwas as follows: sen-
sitivity – 73.3%, speciﬁcity – 77.6%, positive predictive value (PPV)
– 80.0%, and negative predictive value (NPV) – 70.4%.
Conclusion: While performance of the BM1 prognostic test (on
Sri Lankan patients) could not match that of the panel prognostic
test (on Singapore patients), there were considerable improve-
ments in speciﬁcity and PPV over current clinical practices used
(in Singapore) to determine which Dengue patients to hospitalise
(speciﬁcity: ≤55%; PPV: ≤34%).
http://dx.doi.org/10.1016/j.ijid.2016.02.923
